One-Page Truth-Telling Aid for Cancer Disclosure
A One-Page Truth-Telling Aid for Cancer Disclosure in Taiwan: A Two-Arm Pragmatic Randomized Controlled Trial
The goal of this clinical trial is to learn whether a one-page communication aid can improve communication between physicians and patients with cancer during cancer-related truth-telling consultations. The one-page aid is designed to help physicians quickly understand patients' preferences and needs before the consultation.
The main questions it aims to answer are:
- Does the one-page communication aid improve patients' satisfaction with how cancer-related information is explained?
- Does the one-page communication aid reduce patients' emotional distress after the consultation?
- Does the one-page communication aid improve physicians' confidence in communicating cancer-related information?
Researchers will compare patients whose physicians receive the one-page communication aid with patients whose physicians provide usual care with a blank sheet for patients to write down questions. This comparison will help determine whether the one-page aid improves communication, emotional outcomes, and physician confidence.
Participants will:
- Complete questionnaires before and after the consultation
- Receive either the one-page communication aid or a blank sheet, depending on their physician's group
- Complete follow-up questionnaires at 3 months and 6 months after the consultation
Physicians will also complete brief questionnaires about their communication confidence at baseline, 1 week after recruitment of their first enrolled patient, 3 months, and 6 months.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Cancer-related truth-telling is an important but challenging part of oncology care. Patients may differ in how much information they want to receive, how they prefer information to be explained, who they want to be present during the discussion, and what questions or concerns they wish to raise. In routine outpatient settings, physicians often have limited time to identify these individual preferences before discussing cancer-related information.
This study will evaluate a One-Page Truth-Telling Aid designed to help physicians quickly understand patients' disclosure preferences and communication needs before the consultation. The aid is completed with patients before the visit and summarizes key information for the physician, including the patient's preferred way of receiving information, preferred communication style, desired content, and questions the patient would like to ask.
This is a two-arm, single-blind, pragmatic clinical trial. Participating physicians will be assigned to either the experimental group or the control group. Patients will be allocated according to the group assignment of their participating physician. Patients in the experimental group will complete the One-Page Truth-Telling Aid before the consultation and will be encouraged to provide it to their physician at the beginning of the visit. Patients in the control group will receive a blank sheet that they may use to write down questions before the consultation.
The study will assess patient-reported truth-telling experiences, emotional distress, and decisional regret, as well as physician-reported communication confidence. Patient assessments will be conducted before the consultation, immediately after the consultation, and at 3 and 6 months after the consultation. Physician assessments will be conducted before the intervention, 1 week after recruitment of their first enrolled patient, and at 3 and 6 months thereafter.
The study is expected to provide evidence on whether a brief, low-burden communication aid can support patient-centered truth-telling in oncology outpatient care and improve communication-related outcomes for both patients and physicians.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Shih-Ying Chen, PhD
- Telefonnummer: +886-32118800 #5212
- E-Mail: s26871193@cgu.edu.tw
Studienorte
-
-
-
Taoyuan, Taiwan, 33302
- Rekrutierung
- Chang Gung University
-
Kontakt:
- Shih-Ying Chen, PhD
- Telefonnummer: +886-32118800 #5212
- E-Mail: s26871193@cgu.edu.tw
-
Hauptermittler:
- Shih-Ying Chen, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Kind
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
【Physicians】
Inclusion Criteria:
- Physicians who provide clinical care for patients with cancer in participating outpatient departments.
- Physicians who are involved in cancer-related truth-telling or disclosure consultations.
- Physicians who are willing to participate and provide informed consent.
Exclusion Criteria:
- Physicians who are unable or unwilling to complete study procedures or follow-up assessments.
【Patients】
Inclusion Criteria:
- Patients diagnosed with cancer.
- Patients who are scheduled to receive cancer-related information from a participating physician, including information about diagnosis, recurrence, metastasis, end-of-life status.
- Patients who are able to communicate in Mandarin Chinese or Taiwanese.
- Patients who are able to complete questionnaires independently or with assistance from the research assistant.
- Patients who are willing to participate and provide informed consent.
Exclusion Criteria:
- Patients who are unable to provide informed consent.
- Patients with severe cognitive impairment, severe physical illness, or emotional distress that prevents participation, as judged by the clinical team or research staff.
- Patients who are unable to complete the study questionnaires even with assistance.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Versorgungsforschung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: One-Page Truth-Telling Aid
Patients in this arm will receive the One-Page Truth-Telling Aid before the truth-telling consultation.
The aid will be completed with the patient before the visit and summarizes the patient's disclosure preferences, communication needs, and questions for the physician.
Patients will be encouraged to provide the aid to their participating physician at the beginning of the consultation so that the physician can quickly understand the patient's preferences and tailor communication accordingly.
|
The One-Page Truth-Telling Aid is a brief communication aid completed with patients before the consultation.
It summarizes patients' disclosure preferences, communication needs, and questions for the physician.
Patients are encouraged to provide the aid to their participating physician at the beginning of the consultation to support patient-centered communication.
|
|
Aktiver Komparator: Blank Sheet
Patients in this arm will receive a blank sheet before the truth-telling consultation.
The blank sheet may be used to write down questions or concerns the patient would like to discuss with the physician.
It does not include structured questions about disclosure preferences or communication needs.
Patients will receive usual care and may choose whether to provide the blank sheet to their participating physician during the consultation.
|
The blank sheet is provided to patients before the consultation and may be used to write down questions or concerns.
It does not include structured questions about disclosure preferences or communication needs.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patients' Truth-Telling Preferences and Perceptions
Zeitfenster: Baseline, immediately after the truth-telling consultation, 3 months post-intervention, and 6 months post-intervention
|
Patients' truth-telling preferences and perceptions of physicians' actual disclosure practices will be assessed using the 43-item Truth-Telling Questionnaire (TTQ-43).
The TTQ-43 includes four domains: how to deliver bad news, emotional support, additional information, and setting.
Items are scored from 1 to 5, with higher scores indicating stronger preferences expectation at baseline or greater perceived alignment with physician practice at follow-up.
|
Baseline, immediately after the truth-telling consultation, 3 months post-intervention, and 6 months post-intervention
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Patients' Psychological Distress
Zeitfenster: Baseline, immediately after the truth-telling consultation, 3 months post-intervention, and 6 months post-intervention
|
Patients' psychological distress will be assessed using the Depression Anxiety Stress Scale-21 (DASS-21). The DASS-21 includes three subscales: depression, anxiety, and stress. Each subscale score ranges from 0 to 42, with higher scores indicating greater symptom severity. Patients' psychological distress will also be assessed using the Distress Thermometer (DT), a single-item distress screening tool. Scores range from 0 to 10, with higher scores indicating greater distress. A score of 4 or higher indicates clinically relevant distress. |
Baseline, immediately after the truth-telling consultation, 3 months post-intervention, and 6 months post-intervention
|
|
Physicians' Confidence in Communication
Zeitfenster: Baseline, 1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention
|
Physicians' confidence in communication with patients with cancer and their families will be assessed using the 21-item Confidence in Communication with Patients questionnaire.
Items are scored from 1 to 10, with higher scores indicating greater confidence.
|
Baseline, 1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention
|
|
Patients' Decision Regret
Zeitfenster: 3 months post-intervention and 6 months post-intervention
|
Patients' regret regarding their treatment decisions will be assessed using the Decision Regret Scale (DRS).
Scores range from 0 to 100, with higher scores indicating greater decisional regret.
A score greater than 25 indicates moderate to high decisional regret.
|
3 months post-intervention and 6 months post-intervention
|
|
Treatment-Related Adverse Events
Zeitfenster: 3 months post-intervention and 6 months post-intervention
|
Treatment-related adverse events will be evaluated using the Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) based on electronic health record data.
Events are graded from 1 to 5, with higher grades indicating more severe adverse events.
|
3 months post-intervention and 6 months post-intervention
|
|
Medical Expenditure
Zeitfenster: 6 months post-intervention
|
Medical expenditure will be estimated using National Health Insurance points recorded in the electronic health record system, based on the local conversion basis in Taiwan.
|
6 months post-intervention
|
|
Physicians' Perceived Usefulness of the One-Page Truth-Telling Aid
Zeitfenster: 1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention
|
Physicians' perceived usefulness of the One-Page Truth-Telling Aid will be assessed using a single-item rating scale from 0 to 10, with higher scores indicating greater perceived usefulness.
|
1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention
|
|
Physicians' Willingness to Recommend the One-Page Truth-Telling Aid
Zeitfenster: 1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention
|
Physicians' willingness to recommend the One-Page Truth-Telling Aid will be assessed using a single-item rating scale from 0 to 10, with higher scores indicating greater willingness to recommend the aid.
|
1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention
|
|
Patients' Trust in the Physician and Satisfaction With the Disclosure Experience
Zeitfenster: Immediately after the truth-telling consultation
|
Patients' trust in the physician and satisfaction with the disclosure experience will be assessed using single-item rating scales from 0 to 10, with higher scores indicating greater trust and satisfaction.
|
Immediately after the truth-telling consultation
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Shih-Ying Chen, PhD, Chang Gung University
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- NSTC 114-2635-B-182-002 -
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .